Document is current

Article History

Received: 11 January 2025

Accepted: 25 February 2025

First Online: 26 April 2025

Declarations

:

: Personal financial interests: ACB reports receiving lecture grants from Esteve, Lilly, and Astellas; travel support from Amgen; and research funding from HRA Pharma-Esteve. AJMM—consulting or advisory role: Regeneron, Sanofi, Bristol-Myers Squibb/Pfizer, Leo Pharma, Daiichi Sankyo, Incyte, AstraZeneca, MSD Oncology, Lilly, Celgene, Novocure, Roche, Servier; Speakers’ Bureau: Rovi, STADA, Menarini, Bayer; research funding: Celgene, Sanofi, Leo Pharma and Rovi; patents: risk assessment model in venous thromboembolism in cancer patients; travel, accommodation and expenses: AstraZeneca, Amgen, Merck Serono, Roche, Celgene, Pfizer. DCL—consultant or advisory role: AstraZeneca, BMS; speaking: AstraZeneca, BMS, Leo Pharma, Rovi. EGD—consultant or advisory role: Sanofi, Janssen, Astellas, Bayer, Ipsen, Pfizer, Roche, Novartis, Eisai, Recordati, BMS, MSD, AstraZeneca, Merck, Rovi, Daiichi Sankyo, Techdow, Lilly, GSK, advanced accelerator applications; speaking: Astellas, Janssen, Sanofi, Bayer, Ipsen, Pfizer, Roche, BMS, Rovi, Daiichi Sankyo, Leo Pharma, Eisai, Boehringer Ingelheim, Merck, EUSA Pharma/Recordati, Lilly, advanced accelerator applications, GSK; grant support: Astellas, Janssen, Sanofi, Bayer, Ipsen, Ferrer, Pfizer, Roche, GSK, BMS, MSD, Merck, Recordati, AstraZeneca, Advanced accelerator applications; travel/accommodation expenses: Astellas, Janssen, Sanofi, BMS, Bayer, Ipsen, Roche, Novartis, Pfizer, Eisai, AstraZeneca, Leo Pharma. GBL—speaking: MSD, SUNpharma, Pfizer, Pierre Fabre, Bristol Mayer, Roche, Merck, AstraZeneca. IGE—consultant: AstraZeneca, Amgen, Merck, Leo Pharma, Rovi. JML—speaking: GSK, MSD, AstraZeneca; travel, accommodations: Servier, MSD. LOM—speaking: Leo Pharma and Rovi. MLM—honoraria: Servier, Leo Pharma; travel, accommodations and expenses: AstraZeneca, Novartis, Ipsen, Servier, Pharma Mar, Roche. MAR—MR’s department has received a grant from SEOM (Spanish Society of Medical Oncology) for the assessment and completion of statistical analysis. MSC—consultant or advisory role: KyowaKirin; research funding: Leo Pharma; speaking: Leo Pharma. Sanofi. Lundbeck; other: financial support for attending symposia (Sanofi, MSD, Esteve, Amgen, Servier, Angelini, Leo Pharma), financial support for educational programs (Angelini, Sanofi, Rovi, Leo Pharma, Servier, Merck), remunerations for authorship in clinical cases journals/book chapters/complete books (KyowaKirin, Mylan, Leo Pharma). PJF—honoraria for speakers’ bureau participation, and serving on advisory boards from Astellas, AstraZeneca, Bristol-Myers Squibb (BMS), Esteve, Merck Sharp & Dohme (MSD), Novartis, Nutricia, Pfizer, Rovi, Takeda, and Viatri and research grants from Astellas, AstraZeneca, BMS, and MSD. PPS—consultant or advisory role: Roche, BMS, MSD, AstraZeneca, Merck, Rovi, Novocure, LeoPharma; speaking: Roche, BMS, MSD, AstraZeneca, Merck, Rovi, Novocure, LeoPharma; grant support: Roche, BMS, MSD, AstraZeneca, Merck, Rovi, Novocure, LeoPharma; travel/accommodation expenses: Roche, BMS, MSD, AstraZeneca, Merck, Rovi, Novocure, LeoPharma. CIP, CDP, DB, EMC, IGE, JPA, JASC, JTP, MCC, MCVB, MJOM, MRS, POR, RPB, SGA, VECR: the rest of authors declare no competing interests for this manuscript.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: All participants provided informed consent prior to their participation.